1. Home
  2. CERT vs NRIX Comparison

CERT vs NRIX Comparison

Compare CERT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CERT

Certara Inc.

HOLD

Current Price

$7.29

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.89

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
NRIX
Founded
2008
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CERT
NRIX
Price
$7.29
$16.89
Analyst Decision
Buy
Strong Buy
Analyst Count
10
13
Target Price
$12.78
$29.46
AVG Volume (30 Days)
2.2M
1.2M
Earning Date
02-26-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$415,551,000.00
$83,980,000.00
Revenue This Year
$10.75
N/A
Revenue Next Year
$6.32
$20.16
P/E Ratio
$109.10
N/A
Revenue Growth
11.47
53.95
52 Week Low
$7.30
$8.18
52 Week High
$15.69
$22.50

Technical Indicators

Market Signals
Indicator
CERT
NRIX
Relative Strength Index (RSI) 24.85 43.33
Support Level $7.49 $15.87
Resistance Level $10.21 $17.01
Average True Range (ATR) 0.44 1.11
MACD -0.27 -0.29
Stochastic Oscillator 2.38 20.88

Price Performance

Historical Comparison
CERT
NRIX

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: